No "Statistical Alchemy" Here: Meta-Analyses Can Reduce Trial Size
Hints about the direction FDA's Meta-Analysis Working Group may take in drafting guidance, and the Institute of Medicine may adopt in twin reports on the subject, can be found in journal articles by Joseph Lau, a professor of medicine at Tufts who is involved in all three efforts (see 1preceding story)
You may also be interested in...
The question of how to develop meta-analyses of clinical trials that can yield useful information on drug and biologic safety will be the subject of an FDA guidance and an important focus of two reports from the Institute of Medicine
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011